| 1. |
|
|
| 2. |
|
|
| 3. |
- Jendle, Johan, 1963-, et al.
(author)
-
Willingness to pay for diabetes drug therapy in type 2 diabetes patients : based on LEAD clinical programme results
- 2012
-
In: Journal of Medical Economics. - Oxfordshire, United Kingdom : Taylor & Francis. - 1369-6998 .- 1941-837X. ; 15:Suppl 2, s. 1-5
-
Journal article (peer-reviewed)abstract
- Objective: The purpose of this study was to investigate the preferences of people with diabetes for liraglutide vs other glucose lowering drugs, based on outcomes of clinical trials.Methods: Willingness to pay (WTP) for diabetes drug treatment was assessed by combining results from a recent WTP study with analysis of results from the Liraglutide Effect and Action in Diabetes (LEAD) programme. The LEAD programme included six randomised clinical trials with 3967 participants analysing efficacy and safety of liraglutide 1.2 mg (LEAD 1-6 trials), rosiglitazone (LEAD 1 trial), glimepiride (LEAD 2-3 trials), insulin glargine (LEAD 5 trial), and exenatide (LEAD 6 trial). The WTP survey used discrete choice experimental (DCE) methodology to evaluate the convenience and clinical effects of glucose lowering treatments.Results: People with type 2 diabetes were prepared to pay an extra €2.64/day for liraglutide compared with rosiglitazone, an extra €1.94/day compared with glimepiride, an extra €3.36/day compared with insulin glargine, and an extra €0.81/day compared with exenatide. Weight loss was the largest component of WTP for liraglutide compared with rosiglitazone, glimepiride, and insulin glargine. Differences in the administration of the two drugs was the largest component of WTP for liraglutide (once daily anytime) compared with exenatide (twice daily with meals). A limitation of the study was that it was based on six clinical trials where liraglutide was the test drug, but each trial had a different comparator, therefore the clinical effects of liraglutide were much better documented than the comparators.Conclusions: WTP analyses of the clinical results from the LEAD programme suggested that participants with type 2 diabetes were willing to pay appreciably more for liraglutide than other glucose lowering treatments. This was driven by the relative advantage of weight loss compared with rosiglitazone, glimepiride, and insulin glargine, and administration frequency compared with exenatide.
|
|
| 4. |
- Bøgelund, Eva G., et al.
(author)
-
Molecular complexity on disc scales uncovered by ALMA: Chemical composition of the high-mass protostar AFGL 4176
- 2019
-
In: Astronomy and Astrophysics. - : EDP Sciences. - 0004-6361 .- 1432-0746. ; 628
-
Journal article (peer-reviewed)abstract
- Context. The chemical composition of high-mass protostars reflects the physical evolution associated with different stages of star formation. In addition, the spatial distribution and velocity structure of different molecular species provide valuable information on the physical structure of these embedded objects. Despite an increasing number of interferometric studies, there is still a high demand for high angular resolution data to study chemical compositions and velocity structures for these objects. Aims. The molecular inventory of the forming high-mass star AFGL 4176, located at a distance of ∼3.7 kpc, is studied in detail at a high angular resolution of ∼0.35′′, equivalent to ∼1285 au at the distance of AFGL 4176. This high resolution makes it possible to separate the emission associated with the inner hot envelope and disc around the forming star from that of its cool outer envelope. The composition of AFGL 4176 is compared with other high- and low-mass sources, and placed in the broader context of star formation. Methods. Using the Atacama Large Millimeter/submillimeter Array (ALMA) the chemical inventory of AFGL 4176 has been characterised. The high sensitivity of ALMA made it possible to identify weak and optically thin lines and allowed for many isotopologues to be detected, providing a more complete and accurate inventory of the source. For the detected species, excitation temperatures in the range 120-320 K were determined and column densities were derived assuming local thermodynamic equilibrium and using optically thin lines. The spatial distribution of a number of species was studied. Results. A total of 23 different molecular species and their isotopologues are detected in the spectrum towards AFGL 4176. The most abundant species is methanol (CH3OH) with a column density of 5.5 × 1018 cm-2 in a beam of ∼0.3″, derived from its 13C-isotopologue. The remaining species are present at levels between 0.003 and 15% with respect to methanol. Hints that N-bearing species peak slightly closer to the location of the peak continuum emission than the O-bearing species are seen. A single species, propyne (CH3C2H), displays a double-peaked distribution. Conclusions. AFGL 4176 comprises a rich chemical inventory including many complex species present on disc scales. On average, the derived column density ratios, with respect to methanol, of O-bearing species are higher than those derived for N-bearing species by a factor of three. This may indicate that AFGL 4176 is a relatively young source since nitrogen chemistry generally takes longer to evolve in the gas phase. Taking methanol as a reference, the composition of AFGL 4176 more closely resembles that of the low-mass protostar IRAS 16293-2422B than that of high-mass, star-forming regions located near the Galactic centre. This similarity hints that the chemical composition of complex species is already set in the cold cloud stage and implies that AFGL 4176 is a young source whose chemical composition has not yet been strongly processed by the central protostar.
|
|
